Shionogi & Co Ltd (SGIOF) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, time has come to start the meeting. I am Kyokawa, GM at the Public Relations of Shio Nukin Company. Thank you very much for attending the meeting out of your busy schedule. From now, I would like to start the first half of the fiscal 2023 financial result meeting. First, let me introduce the speakers today. First one, Representative, Director, President, and CEO, President, Mr. Tessie Logie. Tessie Logie, nice to see you. And John Keller, the Senior Executive Officer, Senior Vice President, R&D, Verizon Unit. And Mr. Toshinobu Iwasaki, Senior Executive Officer, Senior Vice President, Healthcare Business, Verizon Unit. Mr. Koji Hanasaki, Senior Executive Officer, Senior Vice President of Surprise Supervisory Unit in the Global Business Division. And Ryuchi Kiyama, Senior Executive Officer, Senior Vice President of Corporate Strategy Division. And Takeki Uehara-Lakobu. Research Media Vice President, Drug Development and Regulatory Science Division. And finally, Ms. Masako Kudo, the GM at the Accounting Department. Let me explain the procedure today. First of all, Toshilogi will explain the out view of the quote reclosing until the shareholder returns according to the agenda. And then John Keller will explain about the update. onwards gender update of the COVID-19 treatment drug. And then after that, we will have a Q&A session in the end. And you can use the simultaneous interpretation function today. If you were to use a simultaneous interpretation, please find the globe icon on the bottom of the screen to choose Japanese or English. whichever you like. So let me start, Mr. Teshiirogi, present, please. So as Kyokawa-san explained, for R&D, for COVID-19 treatment, 309-309 drug will be explained about Mr. Uehara. Then after that, this morning, The O...